Homologous News and Research

RSS

Omicron BQ and XBB subvariants most resistant viruses to monoclonal antibodies

A recent study examines the neutralization of SARS-CoV-2 Omicron sub-variants by sera from boosted individuals and those with breakthrough infection.

13 Feb 2023

Vaccine efficacy and booster dose combinations among 18.9 million adults in the early phase of Omicron

A new study in the journal Clinical Infectious Diseases aimed to determine the relative vaccine effectiveness (rVE) in three different recipient cohorts, those who received the Ad26.COV2.S vaccine followed by Ad26.COV2.S booster, those who received the Ad26.COV2.S vaccine followed by an mRNA booster, and those who received two doses of an mRNA vaccine followed by an mRNA booster.

12 Feb 2023

Study suggests SARS-CoV-2 is likely to only infect placental mammals

Researchers perform ontological and taxonomical analysis of human coronavirus hosts.

9 Feb 2023

Heterologous inactivated virus/mRNA booster strongly augments response to BF.7, BQ.1.1, and XBB.1

Heterologous vaccination improves the neutralization of SARS-CoV-2 Omicron sub-variants.

9 Feb 2023

Study characterizes mutations in neuraminidase of human-like H5N1 influenza viruses

A study published in PLOS PATHOGENS describes the prevalence and functions of mutations in neuraminidase enzyme of avian H5N1 influenza viruses that are preferentially selected in human H5N1 influenza viruses.

7 Feb 2023

The effectiveness of intranasal COVID-19 vaccination in healthy adults

A recent study discusses the safety profiles and immunogenicity of the nasal BBV154 COVID-19 vaccine in healthy adults.

3 Feb 2023

Researchers report a heterologous vaccination strategy against IBV in Chickens

Researchers reported on the immunogenicity of a heterologous vaccine regimen against IBV, comprising prime doses of QAC-encapsulated plasmid and a booster dose of MVA.

2 Feb 2023

Could novel lineages eventually dominate the viral population?

A new study puts forward a bottom-up approach to quickly predict whether a lineage will dominate the viral population, at a particular geographical location.

1 Feb 2023

Third booster dose of SARS-CoV-2 vaccine associated with 90% reduction in COVID-19 deaths

A booster (third) dose of a SARS-CoV-2 vaccine was associated with a 90% reduction in death in people with multiple health conditions compared to 2 doses, according to a new study from Hong Kong published in CMAJ.

30 Jan 2023

Study evaluates SARS-CoV-2-specific antibody response in human milk

In a recent study published in the journal Communications Biology, researchers investigated the effect of the coronavirus disease 2019 (COVID-19) vaccine booster on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-specific antibodies in the milk of lactating women. Additionally, they explored whether the booster-induced antibody response differed from the homologous and heterologous boosting schedule of their primary vaccination.

29 Jan 2023

Phase I trial results from AdaptVac's COVID capsid virus-like particle vaccine

In a recent study published in The Lancet Microbe journal, researchers described the effectiveness of a modular capsid virus-like coronavirus disease 2019 (COVID-19) vaccination.

22 Jan 2023

Longitudinal assessment of immunoglobulin G antibody responses to messenger ribonucleic acid vaccination doses and breakthrough infections

Researchers evaluated immunoglobulin G (IgG) responses to coronavirus disease 2019 (COVID-19) messenger ribonucleic acid (mRNA) vaccinations.

20 Jan 2023

The "Great Escape" by SARS-CoV-2 XBB.1

In a recent article published in the Lancet Microbe, researchers in the Netherlands and the United Kingdom quantified the antigenic diversity of new severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) subvariants, BQ.1.1, BM.1.1.1, and XBB.1, all derivatives of the variant of concern (VOC) Omicron, which emerged in late 2022.

17 Jan 2023

Researchers explore immune responses to mpox infections

In new research, researchers demonstrated that individuals recovering from mpox virus (MPXV) infection have neutralizing antibodies that target MPXV antigens A35R and H3L.

17 Jan 2023

Recent findings on original antigenic sin and SARS-CoV-2

Researchers collated the findings of studies relating original antigenic sin with SARS-CoV-2 evolution.

13 Jan 2023

Bivalent boosters tested against all SARS-CoV-2 Omicron lineages

In a recent study posted to the bioRxiv* preprint server, researchers in the United States assessed the impact of the bivalent messenger ribonucleic acid (mRNA) severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine on the antibody-mediated neutralization of the SARS-CoV-2 Omicron lineages.

11 Jan 2023